Recent news on Daunoxome

Quest Group International, Inc. Raises $20 Million, Acquires ...  -  May 18, 2007
PharmaLive.com (press release),He has played a pivotal role in the development of three marketed drugs including Taxol(R) Paxene(R) and DaunoXome(R) and has served on FDA Advisory

Diatos Strengthens Management Team with the Appointment of New ...  Oct 9, 2006
...strategic oncology marketing, business development and affiliate marketing and sales across their haemato-oncology portfolio, including DaunoXome ® which was ... -Business Wire (press release), Examine Emerging Opportunities in Cancer Nanomedicine With This ...  Sep 4, 2006
Abraxane - Abraxis BioScience/AstraZeneca - DaunoXome - Gilead Sciences/Diatos - CellSearch Circulating Tumor Cell Kit - Immunicon - Bio-barcode and Verigen ... -International News Service



French biotech Diatos buys DaunoXome rights from Gilead  May 11, 2006
...on the worldwide development and commercialization rights to DaunoXome. DaunoXome is a marketed liposomal formulation of daunorubicin ... - MarketWatch

Diatos koopt kankermedicijn DaunoXome van Gilead Sciences  May 11, 2006
BW)(DIATOS) Diatos Announces Acquisition of Specialty Cancer Product DaunoXome(R) from ... on the worldwide development and commercialization rights to DaunoXome. ... - Netherlands Corporate News (persbericht)

Diatos Plans to Go Public  May 15, 2006
Last week Diatos added to its arsenal, announcing it will pay up to $4.7 million for the exclusive worldwide rights to DaunoXome, an approved treatment for ... - Red Herring

UPDATE 1-France's Diatos set for IPO after Gilead drug deal  May 11, 2006
...(GILD.O: Quote, Profile, Research) up to $4.7 million, plus royalties on future sales, for rights to DaunoXome, a niche product for treating AIDS-related ... - Reuters

IPO prospect Diatos buys Gilead cancer drug  May 11, 2006
...it was paying Gilead Sciences Inc (GILD.O: Quote, Profile, Research) up to $4.7 million, plus royalties on future sales, for rights to DaunoXome, a niche ... - Reuters

Diatos licenses Gilead anticancer drug  May 12, 2006
DaunoXome, liposomal formulation of daunorubicin, is already sold by Gilead in more than 20 countries for AIDS/HIV-related Kaposi's sarcoma. ... - Pharmaceutical Business Review





Positive results for Bioenvision's Evoltra  Apr 7, 2006
The company now plans to take the drug into phase III testing. Daunorubicin was sold by NeXstar Pharmaceuticals of California under the name DaunoXome. ... - Pharmaceutical Business Review

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional